Pliant Therapeutics, Inc. is a US-based biopharmaceutical company which discovers, develops, and commercializes novel therapies focusing on fibrosis and related diseases. Its lead product candidate PLN-74809 is currently under three Phase 2a trials, while PLN-1474 completed Phase 1 clinical trial for the treatment of liver fibrosis. The company is also developing two additional preclinical integrin-based programs, including an oncology program and a muscular dystrophy program.